semaglutide and arrhythmia Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review meta-analysis of randomized controlled trials Frontiers | Effect of semaglutide

Find more articles like this one in our learning center here

This anti-lipogenic activity is hypothesized to involve inhibition of acetyl-CoA carboxylase, the rate-limiting enzyme in de novo lipogenesis

It contains semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist

Gut microbiota are modulated by several factors including diet, genetics, circadian rhythms, anti-obesity medications, probiotics as well as antibiotics (15)

Slows the breakdown of carbohydrates in the gut

Patients experiencing frequent vomiting should be monitored for signs of dehydration and may require temporary dose reduction or supportive care measures